Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. NICE technology appraisal guidance 425
National Institute for Health and Care Excellence (NICE)
Record ID 32018011522
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta425
Year Published:
2016
URL for published report:
https://www.nice.org.uk/guidance/ta425
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Leukemia, Myeloid, Chronic-Phase
- Dasatinib
- Imatinib Mesylate
- Antineoplastic Combined Chemotherapy Protocols
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Protein Kinase Inhibitors
- Pyrimidines
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.